AssetMark’s Celldex Therapeutics CLDX Stock Holding History
Bought
Maintained
Sold
Other funds holding CLDX
AssetMark's CLDX Position: Q3 2026 in Review
AssetMark held its Celldex Therapeutics (CLDX) position steady in Q3 2026 at 21 shares worth $681. The position accounts for ﹤0.01% of the portfolio, ranked #3326.
AssetMark first reported a position in CLDX in Q2 2024 and has held it in 5 quarters since. The position peaked at $781 in Q2 2026. 166 funds tracked by Wall St. Rank hold CLDX as of Q3 2026.
- AssetMark held 21 shares of Celldex Therapeutics worth $681 as of Q3 2026.
- AssetMark left its Celldex Therapeutics share count unchanged in Q3 2026.
- Celldex Therapeutics made up ﹤0.01% of AssetMark's portfolio in Q3 2026, its #3326 holding.
- AssetMark first reported a position in Celldex Therapeutics in Q2 2024 and has held it in 5 quarters since.
- AssetMark's Celldex Therapeutics position peaked at $781 in Q2 2026.
- 166 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2026.
Based on AssetMark's 13F filing for Q3 2026, filed 21 Oct 2026.